Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands: bringing "the lead" into PSMA-targeted alpha therapy?
PURPOSE: The aims of this study were to develop a prostate-specific membrane antigen (PSMA) ligand for labelling with different radioisotopes of lead and to obtain an approximation of the dosimetry of a simulated 212Pb-based alpha therapy using its 203Pb imaging analogue. - METHODS: Four novel Glu-u...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
3 January 2019
|
| In: |
European journal of nuclear medicine and molecular imaging
Year: 2019, Jahrgang: 46, Heft: 5, Pages: 1081-1091 |
| ISSN: | 1619-7089 |
| DOI: | 10.1007/s00259-018-4220-z |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1007/s00259-018-4220-z
|
| Verfasserangaben: | José Carlos Dos Santos, Martin Schäfer, Ulrike Bauder-Wüst, Wencke Lehnert, Karin Leotta, Alfred Morgenstern, Klaus Kopka, Uwe Haberkorn, Walter Mier, Clemens Kratochwil |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1666413399 | ||
| 003 | DE-627 | ||
| 005 | 20240323101136.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190528s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00259-018-4220-z |2 doi | |
| 035 | |a (DE-627)1666413399 | ||
| 035 | |a (DE-599)KXP1666413399 | ||
| 035 | |a (OCoLC)1341225727 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Santos, José Carlos dos |d 1980- |e VerfasserIn |0 (DE-588)1187285749 |0 (DE-627)1666416495 |4 aut | |
| 245 | 1 | 0 | |a Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands |b bringing "the lead" into PSMA-targeted alpha therapy? |c José Carlos Dos Santos, Martin Schäfer, Ulrike Bauder-Wüst, Wencke Lehnert, Karin Leotta, Alfred Morgenstern, Klaus Kopka, Uwe Haberkorn, Walter Mier, Clemens Kratochwil |
| 264 | 1 | |c 3 January 2019 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Im Titel ist "203" und "212" hochgestellt | ||
| 500 | |a Gesehen am 28.05.2019 | ||
| 520 | |a PURPOSE: The aims of this study were to develop a prostate-specific membrane antigen (PSMA) ligand for labelling with different radioisotopes of lead and to obtain an approximation of the dosimetry of a simulated 212Pb-based alpha therapy using its 203Pb imaging analogue. - METHODS: Four novel Glu-urea-based ligands containing the chelators p-SCN-Bn-TCMC or DO3AM were synthesized. Affinity and PSMA-specific internalization were studied in C4-2 cells, and biodistribution in C4-2 tumour-bearing mice. The most promising compound, 203Pb-CA012, was transferred to clinical use. Two patients underwent planar scintigraphy scans at 0.4, 4, 18, 28 and 42 h after injection, together with urine and blood sampling. The time-activity curves of source organs were extrapolated from 203Pb to 212Pb and the calculated residence times of 212Pb were forwarded to its unstable daughter nuclides. QDOSE and OLINDA were used for dosimetry calculations. - RESULTS: In vitro, all ligands showed low nanomolar binding affinities for PSMA. CA09 and CA012 additionally showed specific ligand-induced internalization of 27.4 ± 2.4 and 15.6 ± 2.1 %ID/106 cells, respectively. The 203Pb-labelled PSMA ligands were stable in serum for 72 h. In vivo, CA012 showed higher specific uptake in tumours than in other organs, and particularly showed rapid kidney clearance from 5.1 ± 2.5%ID/g at 1 h after injection to 0.9 ± 0.1%ID/g at 24 h. In patients, the estimated effective dose from 250-300 MBq of diagnostic 203Pb-CA012 was 6-7 mSv. Assuming instant decay of daughter nuclides, the equivalent doses projected from a therapeutic activity of 100 MBq of 212Pb-CA012 were 0.6 SvRBE5 to the red marrow, 4.3 SvRBE5 to the salivary glands, 4.9 SvRBE5 to the kidneys, 0.7 SvRBE5 to the liver and 0.2 SvRBE5 to other organs; representative tumour lesions averaged 13.2 SvRBE5 (where RBE5 is relative biological effectiveness factor 5). Compared to clinical experience with 213Bi-PSMA-617 and 225Ac-PSMA-617, the projected maximum tolerable dose was about 150 MBq per cycle. - CONCLUSION: 212Pb-CA012 is a promising candidate for PSMA-targeted alpha therapy of prostate cancer. The dosimetry estimate for radiopharmaceuticals decaying with the release of unstable daughter nuclides has some inherent limitations, thus clinical translation should be done cautiously. | ||
| 650 | 4 | |a 212Pb-CA012 | |
| 650 | 4 | |a Dosimetry | |
| 650 | 4 | |a Prostate cancer | |
| 650 | 4 | |a PSMA-targeted alpha therapy | |
| 700 | 1 | |a Haberkorn, Uwe |d 1959- |e VerfasserIn |0 (DE-588)1022913905 |0 (DE-627)717331245 |0 (DE-576)366166352 |4 aut | |
| 700 | 1 | |a Mier, Walter |d 1966- |e VerfasserIn |0 (DE-588)12029026X |0 (DE-627)69653567X |0 (DE-576)292141599 |4 aut | |
| 700 | 1 | |a Kratochwil, Clemens |d 1978- |e VerfasserIn |0 (DE-588)134026276 |0 (DE-627)559871686 |0 (DE-576)300262787 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of nuclear medicine and molecular imaging |d Heidelberg [u.a.] : Springer-Verl., 2002 |g 46(2019), 5, Seite 1081-1091 |h Online-Ressource |w (DE-627)359787258 |w (DE-600)2098375-X |w (DE-576)110279549 |x 1619-7089 |7 nnas |a Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands bringing "the lead" into PSMA-targeted alpha therapy? |
| 773 | 1 | 8 | |g volume:46 |g year:2019 |g number:5 |g pages:1081-1091 |g extent:11 |a Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands bringing "the lead" into PSMA-targeted alpha therapy? |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00259-018-4220-z |x Verlag |x Resolving-System |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190528 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 134026276 |a Kratochwil, Clemens |m 134026276:Kratochwil, Clemens |d 910000 |d 911400 |e 910000PK134026276 |e 911400PK134026276 |k 0/910000/ |k 1/910000/911400/ |p 10 |y j | ||
| 998 | |g 12029026X |a Mier, Walter |m 12029026X:Mier, Walter |d 910000 |d 911400 |e 910000PM12029026X |e 911400PM12029026X |k 0/910000/ |k 1/910000/911400/ |p 9 | ||
| 998 | |g 1022913905 |a Haberkorn, Uwe |m 1022913905:Haberkorn, Uwe |d 910000 |d 911400 |e 910000PH1022913905 |e 911400PH1022913905 |k 0/910000/ |k 1/910000/911400/ |p 8 | ||
| 998 | |g 1187285749 |a Santos, José Carlos dos |m 1187285749:Santos, José Carlos dos |d 910000 |d 911400 |e 910000PS1187285749 |e 911400PS1187285749 |k 0/910000/ |k 1/910000/911400/ |p 1 |x j | ||
| 999 | |a KXP-PPN1666413399 |e 3479984657 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"disp":"Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands bringing \"the lead\" into PSMA-targeted alpha therapy?European journal of nuclear medicine and molecular imaging","type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["29.2002 -"],"note":["Gesehen am 13.02.2023","Ungezählte Beil.: Supplement"],"language":["eng"],"part":{"volume":"46","year":"2019","text":"46(2019), 5, Seite 1081-1091","pages":"1081-1091","extent":"11","issue":"5"},"origin":[{"publisherPlace":"Heidelberg [u.a.]","dateIssuedKey":"2002","dateIssuedDisp":"2002-","publisher":"Springer-Verl."}],"title":[{"title_sort":"European journal of nuclear medicine and molecular imaging","title":"European journal of nuclear medicine and molecular imaging","subtitle":"official journal of the European Association of Nuclear Medicine (EANM)"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["1619-7089"],"eki":["359787258"],"zdb":["2098375-X"]},"recId":"359787258"}],"origin":[{"dateIssuedDisp":"3 January 2019","dateIssuedKey":"2019"}],"title":[{"title_sort":"Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands","subtitle":"bringing \"the lead\" into PSMA-targeted alpha therapy?","title":"Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"eki":["1666413399"],"doi":["10.1007/s00259-018-4220-z"]},"physDesc":[{"extent":"11 S."}],"person":[{"family":"Santos","role":"aut","display":"Santos, José Carlos dos","given":"José Carlos dos"},{"role":"aut","family":"Haberkorn","display":"Haberkorn, Uwe","given":"Uwe"},{"display":"Mier, Walter","given":"Walter","family":"Mier","role":"aut"},{"role":"aut","family":"Kratochwil","given":"Clemens","display":"Kratochwil, Clemens"}],"recId":"1666413399","note":["Im Titel ist \"203\" und \"212\" hochgestellt","Gesehen am 28.05.2019"],"language":["eng"],"name":{"displayForm":["José Carlos Dos Santos, Martin Schäfer, Ulrike Bauder-Wüst, Wencke Lehnert, Karin Leotta, Alfred Morgenstern, Klaus Kopka, Uwe Haberkorn, Walter Mier, Clemens Kratochwil"]}} | ||
| SRT | |a SANTOSJOSEDEVELOPMEN3201 | ||